This randomized, placebo-controlled, double-blind clinical trial investigated the efficacy and effects of arthrocen treatment on cytokine changes in people having osteoarthritis of the knee.

Participants were randomly segregated to get either 300 mg/day arthrocen (n = 61) or placebo (n = 58) for three months. Collection of data was done utilizing questionnaires including Lequesne index of severity for osteoarthritis of the knee (LISOK), the Western Ontario and McMaster Universities osteoarthritis index (WOMAC), 20-item short form survey (SF-20), and visual analog scale (VAS) as pain quality indices.

With the aid of an ELISA reader, the serum levels of interleukins 2 (IL-2), IL-17α, IL-10, IL-4, and tumor necrosis factor-alpha were estimated.

Participants were randomly segregated to get either 300 mg/day arthrocen (n = 61) or placebo (n = 58) for three months. Collection of data was done utilizing questionnaires including Lequesne index of severity for osteoarthritis of the knee (LISOK), the Western Ontario and McMaster Universities osteoarthritis index (WOMAC), 20-item short form survey (SF-20), and visual analog scale (VAS) as pain quality indices.

With the aid of an ELISA reader, the serum levels of interleukins 2 (IL-2), IL-17α, IL-10, IL-4, and tumor necrosis factor-alpha were estimated.

Arthrocen (avocado/soy unsaponifiables) supplementation may lead to remarkable improvements in  quality of life, activities of daily living, and pain without eliciting any adverse effects in the long term.